Some patients with Attention Deficit Hyperactivity Disorder (ADHD) in Western Australia are dispensed more stimulant medication than they need.

The Queensland University of Technology is conducting a study to see if daily doses of fish oil can help children suffering from attention deficit disorder (ADD).

Researchers have also employed this technology for use in special 'night lights'
Scientists at John Carroll University, working in its Lighting Innovations Institute, have developed an affordable accessory that appears to reduce the symptoms of ADHD. Their discovery also has also been shown to improve sleep patterns among people who have difficulty falling asleep.

In youth with attention deficit hyperactivity disorder (ADHD), the brain matures in a normal pattern but is delayed three years in some regions, on average, compared to youth without the disorder, an imaging study by researchers at the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH) has revealed.

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, yesterday announced results of a national survey where 60 percent of 121 mothers reported their 6 to12 year old child’s once-daily Attention Deficit Hyperactivity Disorder (ADHD) medication stopped working before 6 p.m.

Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA® OROS® methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years.

According to a small-scale, in-office, observational study, psychiatrists and parents have significantly different perceptions of the importance of pediatric ADHD and psychiatric comorbidities, particularly regarding the patients’ most concerning behavior.

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE™ (lisdexamfetamine dimesylate), the first prodrug stimulant.

While working with parents of children with attention deficit hyperactivity disorder (ADHD) at the University at Buffalo, Gregory A. Fabiano noticed something was missing: the fathers.

Non-medicinal interventions are highly effective in preventing the behavioral and academic problems associated with Attention Deficit Hyperactivity Disorder (ADHD), according to a five-year study led by researchers at Lehigh University’s College of Education.

A variant of the dopamine receptor gene may be associated with attention deficit hyperactivity disorder (ADHD) and with thinner tissue in areas of the brain that handle attention, but also appears associated with better clinical outcomes among individuals with the disorder, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.